Summary
We report here sensitive and specific measurement of immune responses of patients with certain kinds of carcinoma toward the physically and chemically well defined T antigen isolated from healthy human erythrocytes. Over 90% of adenocarcinoma tissues tested possess T-specific immunoreactive structures as determined withhuman antisera, in contrast to healthy tissues and benign lesions. Adenocarcinoma patients recognize the carcinoma-associated T antigen as foreign. Delayed-type skin hypersensitivity reaction to T antigen (DTHR-T) was positive in all 25 lung adenocarcinoma patients tested, in 88% of 101 patients with ductal, in 43% of 30 patients with lobular or tubular breast carcinoma and in 9/9 patients with adenocarcinoma of body cavities. Patients of all Stages reacted positively. All 7 patients with small cell lung carcinoma and 3/5 with malignant melanoma had a positive DTHR-T. None of 17 patients with malignant brain tumors, leukemia or Hodgkin's disease, sarcoma or thyroid carcinoma reacted. The DTHR-T was specific in that all 77 healthy persons and 48/49 with other diseases, including 23/24 with non-cancer lung disease were negative; one patient with organizing interstitial pneumonitis was positive. This points to a possible source of false positive reactions. 91% of 149 patients with histologically benign breast disease had a negative DTHR-T; the histology of some of the positive ones was reexamined, 2 proved to have carcinoma in situ.
In vitro leukocyte migration inhibition and scoring of anti-T hemagglutinin titer using the T-anti-T system diagnosed many adenocarcinomata correctly, including 4 whose histology, while turning positive later, was negative at the time. However, these tests were generally less sensitive and specific than the DTHR-T.
This system may also be of screening and monitoring value. Surgical removal of primary carcinoma led to a rebound of anti-T in breast carcinoma patients and its renewed decrease in some, prior to clinical recurrence of cancer. Also, the DTHR-T turned from positive to negative in some Stages I and II breast-and T1–2 N0–1 M0 lung adenocarcinoma patients who had no demonstrable relapse during the ensuing observation period.
Zusammenfassung
Wir berichten hier über sensitive und spezifische Bestimmung der Immunatwort von Patienten mit Brust- und Lungenadenokarzinom gegen das physikalisch und chemische definierte T Antigen, isoliert von menschlichen Erythrozyten. Über 90% der untersuchten Adenokarzinomgewebe besaßen T-spezifische immunreactive Strukturen, gemessen mithuman-anti-T Seren, im Gegensatz zu gesunden und gutartig veränderten Geweben. Bei Adenokarzinomträgern wird das karzinom-assoziierte T Antigen vom Organismus als fremd erkannt. Die verzögerte Hautüberempfindlichkeitsreaktion gegen T Antigen (DTHR-T) war in allen 25 Patienten mit Lungenadenokarzinom positiv, in 88% von 101 Patienten mit ductulärem, in 43% von 30 mit lobulärem oder tubulärem Mammakarzinom sowie in 9/9 Patienten mit Körperhöhlen-Adenokarzinomen. Alle 7 Patienten mit kleinzelligem Lungenkarzinom und 3/5 mit malignem Melanom reagierten positiv. Die DTHR-T war negativ in allen 17 Patienten mit malignen Hirntumoren, Leukämien, Hodgkin, Sarkom und Schilddrüsenkrebs. Die DTHR-T war spezifisch: alle 77 gesunden und 48/49 Personen mit nichtkrebsigen Erkrankungen einschließlich 23/24 Lungenpatienten hatten eine negative DTHR-T; ein Patient mit organisierender interstitieller Pneumonitis reagierte positiv; dies deutet auf eine mögliche Fehlerquelle hin. 91% von 149 Patienten, histologisch als gutartige Brusterkrankung diagnostiziert, hatten eine negative DTHR-T; die Histologie einiger positiv reagierender Patienten wurde reexaminiert und erwies sich in 2 Fällen als in situ Karzinom.
In vitro „Leukocyte migration inhibition“ und „scoring“ der anti-T Agglutinine ergaben eine korrekte Diagnose bei vielen Adenokarzinomen einschließlich 4 Fällen, die zur Zeit unserer positiven Resultate eine negative Histologie hatten, bei denen spätere Biopsien aber positiv ausfielen. Im allgemeinen waren die in vitro Teste weniger sensitiv und spezifisch als die DTHR-T.
Das T-anti-T System könnte sich auch zum „screening“ und „monitoring“ eignen. Chirurgische Entfernung des Primärkarzinoms führte zu einem „rebound“ des anti-T Titers in Brustkrebspatienten, erneuter Abfall wurde in einigen Fällen vor klinischem Rückfall beobachtet. Positive DTHR-T wurde wieder negativ in mehreren Fällen von Brustkrebs Stage I und II bzw. Lungenadenokarzinom T1–2 N0–1 M0; diese Patienten hatten in der folgenden Beobachtungszeit keinen klinischen Rückfall.
Similar content being viewed by others
References
Anglin JH Jr, Lerner MP, Nordquist RE (1977) Blood group-like activity released by human mammary carcinoma cells in culture. Nature 269:254–255
Bird GWG (1964) Anti-T in peanuts. Vox Sang 9:748–749
Black MM, Leis HP Jr, Shore B, Zachrau RE (1974) Cellular hypersensitivity to breast cancer. Cancer 33:952–958
Black MM, Speer FD (1959) Immunology of cancer. Surg Gynecol Obstet 109:105–116
Boccardi V, Attinà D, Girelli G (1974) Influence of orally administered antibiotics on anti-T agglutinin of normal subjects and cirrhotic patients. Vox Sang 27:268–272
Boyd W (1921) Tissue resistance in malignant disease. Surg Gynecol Obstet 32:306–310
Bray J, Lemieux RU, McPherson TA (1981) Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes. J Immunol 126:1966–1969
Caselitz FH, Stein G (1953) Experimentelle Beiträge zum Problem der Hämagglutination nach Thomsen. Z Immun Forsch 110:165–184
Caspar M (1967) Johannes Kepler's Weltharmonik: Transl ofHarmonices Mundi (Linz, Austria, 1619). Oldenbourg, Muenchen, p 8
Codington JF, Sanford BH, Jeanloz RW (1972) Glycoprotein coat of the TA3 cell. Isolation and partial characterization of a sialic acid containing glycoprotein fraction. Biochem 11:2559–2564
Desai PR, Springer GF (1979) Biosynthesis of blood group T-, N-, and M-specific immunodeterminants on human erythrocyte antigens. J Immunogenet 6:403–417
Duncan W, Kerr GR (1976) The curability of breast cancer. Br Med J 2:781–783
Ehrlich P (1909) Über den jetzigen Stand der Karzinomforschung. Ned T Genesk 1:273–290
Fisher B (1976) Some thoughts concerning the primary therapy of breast cancer. In: Breast cancer: a multidisciplinary approach. Springer, Berlin, Heidelberg New York, pp 150–163
Fisher ER, Gregorio RM, Fisher B (1975) The pathology of invasive breast cancer. Cancer 36:1–85
Fournier vD, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V (1980) Growth rate of 147 mammary carcinomas. Cancer 45:2198–2207
Friedenreich V (1930) The Thomsen hemagglutination phenomenon. Levin & Munksgaard, Copenhagen
Gallager HS (1977) View from the giant's shoulder. Cancer 40:185–194.
Gottschalk A (1960) The chemistry and biology of sialic acid and related substances. Cambridge University Press, Cambridge, p 98
Hauschka TS, Weiss L, Holdridge BA, Cudney TL, Zumpft M, Planinsek JA (1971) Karyotypic and surface features of murine TA3 carcinoma cells during immunoselection in mice and rats. J Natl Cancer Inst 47:343–359
Hirszfeld L, Halber W, Laskowski J (1930) Untersuchungen über die serologischen Eigenschaften der Gewebe. I. Mitteilung. Über gruppenspezifische Differenzierung der Normal- und Krebsgewebe. Z Immun Forsch Exp Ther 64:61–80
Hollinshead AC, Stewart THM, Herberman RB (1974) Delayed-hypersensitivity reactions to soluble membrane antigens of human malignant lung cells. J Natl Cancer Inst 52:327–338
Howard DR, Ferguson P, Batsakis JG (1981) Carcinoma-associated cytostructural antigenic alterations: detection by lectin binding. Cancer 47:2872–2877
Howard DR, Taylor CR (1980) An antitumor antibody in normal human serum: Reaction of anti-T with breast carcinoma cells. Oncology 37:142–148
Hughes LE, Lytton B (1964) Antigenic properties of human tumours: delayed cutaneous hypersensitivity reactions. Br Med J 209–212
Kabat EA (1968) Structural concepts in immunology and immunochemistry. Holt, Rinehart, Winston, Inc., New York
Kusama S, Spratt JS Jr, Donegan WL, Watson FK, Cunningham C (1972) The gross rates of growth of human mammary carcinoma. Cancer 30:594–599
Laurent JC, Noël P, Faucon M (1978) Expression of a cryptic cell surface antigen in primary cell cultures from human breast cancer. Biomedicine 29:260–261
Lehmann-Facius H (1931) Über gruppenspezifische und heterogene Strukturen in Lipoidantigenen bösartiger Geschwülste. Frkft Z Pathol 41:521–594
Limas C, Lange P (1980) Altered reactivity for A, B, H antigens in transitional cell carcinomas of the urinary bladder. Cancer 46:1366–1373
Lotan R, Skutelsky E, Danon D, Sharon N (1975) The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogæa). J Biol Chem 250:8518–8523
Luner SJ, Wile AG, Sparks FC (1977) Antibody to T and Tn antigens in patients with breast cancer. Proc Am Assoc Cancer Res, Abstr 375
McCluskey RT, Benacerraf B, McCluskey JW (1963) Studies on the specificity of the cellular infiltrate in delayed hypersensitivity reactions. J Immunol 90:466–477
Newman RA, Klein P, Redland P (1979) Binding of peanut lectin to breast epithelium, human carcinomas, and a cultured rat mammary stem cell: Use of the lectin as a marker of mammary differentiation. J Natl Cancer Inst 63:1339–1346
Old LJ (1981) Cancer immunology: the search for specificity. GHA Clowes memorial lecture. Cancer Res 41:361–375
Ozzello L, Sanpitak P (1970) Epithelial-stromal junction of intraductal carcinoma of the breast. Cancer 26:1186–1198
Pereira MEA, Kabat EA, Lotan R, Sharon N (1976) Immunochemical studies on the specificity of the peanut (Arachis hypogaea) agglutinin. Carbohyd Res 51:107–118
Ray PK, Idiculla A, Mark R, Rhoads JE Jr, Thomas H, Bassett JG, Cooper DR (1981) Extracorporeal immunoadsorption of plasma from a metastatic colon carcinoma patient by protein A-containing non-viable staphylococcus aureus. Clinical, biochemical, serological, and histological evaluation of the patient's response. Cancer (in press)
Richerson HB, Dvorak HF, Leskowitz S (1970) Cutaneous basophil sensitivity, a new look at the Jones-Mote Reaction, general characteristics. J Exp Med 132:546–556
Rosenow EC, Carr DJ (1979) Bronchogenic carcinoma. Ca — A Cancer J Clinicians 29:233–245
Sams WM (1980) Necrotizing vasculitis. J Am Acad Dermatol 3:1–13
Scanlon EF (1981) The early diagnosis of breast cancer. Cancer 48:523–526
Sellei J (1981) The occurrence of Thomsen-Friedenreich receptors in bovine erythrocytes of various FV genotypes. J Immunogenet 8:263–269
Spencer H (1977) Pathology of the lung, vol 2. Saunders, Philadelphia, p 873
Springer GF (1971) Blood-group and Forssman antigenic determinants shared between microbes and mammalian cells. Prog Allergy 15:9–77
Springer GF (1977) Enzyme-treated erythrocytes and inhibition of hemagglutination by antibodies and antibody-like reagents in semiquantitative tube tests. In: Methods in immunology and immunochemistry, vol. 4. Academic Press, New York, pp 14–19, 67–72
Springer GF, Ansell NJ (1958) Inactivation of human erythrocyte agglutinogens M and N by influenza viruses and receptor-destroying enzyme. Proc Natl Acad Sci (USA) 44:182–189
Springer GF, Cantrell JL, Desai PR, Tegtmeyer H (1982) Human blood group M-, N-, T- and Tn-specific substances in lipidic extracts of line-10 hepatocarcinoma of Strain-2 guinea pigs. Clin Immunol Immunopathol 20, (in press)
Springer GF, Codington JF, Jeanloz RW (1972) Surface glycoprotein from a mouse tumor cell as specific inhibitor of antihuman blood-group N agglutinin. J Natl Cancer Inst 49:1469–1470
Springer GF, Desai PR (1974) Common precursors of human blood group MN specificities. Biochem Biophys Res Comm 61:470–475
Springer GF, Desai PR (1975) Human blood-group MN and precursor specificities: structural and biological aspects. Carbohyd Res 40:183–192
Springer GF, Desai PR (1977) Human blood group MN precursor specificities in enterobacteriaceae and their lipopolysaccharides. Am Soc Microbiol Ann Meet, Abstr 88
Springer GF, Desai PR (1974) Relation of human blood-groups MN to cancer cell surface antigens and to receptors for oncogenic viruses. Ann Clin Lab Sci 4:294–298
Springer GF, Desai PR, Banatwala I (1974) Blood group MN specific substances and precursors in normal and malignant human breast tissues. Naturwissenschaften 61:457–458
Springer GF, Desai PR, Banatwala I (1975) Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J Natl Cancer Inst 54:335–339
Springer GF, Desai PR, Murthy MS (1978) Letter to the Editor, Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue sections. Klin Wochenschr 56:1225–1226
Springer GF, Desai PR, Murthy MS, Tegtmeyer H, Scanlon EF (1979) Human carcinoma-associated precursor antigens of the blood group MN system and the host's immune responses to them. Prog Allergy 26:42–96
Springer GF, Desai PR, Scanlon EF (1976) Blood group MN precursors as human breast carcinoma-associated antigens and “naturally” occurring human cytotoxins against them. Cancer 37:169–176
Springer GF, Desai PR, Schachter H, Narasimhan S (1976) Enzymatic synthesis of human blood group M-, N- and T-specific structures. Naturwissenschaften 63:488–489
Springer GF, Murthy MS, Desai PR, Scanlon EF (1980) Breast cancer patient's cell-mediated immune response to Thomsen-Friedenreich (T) antigen. Cancer 45:2949–2954
Springer GF, Nagai Y, Tegtmeyer H (1966) Isolation and properties of human blood group NN and meconium-Vg antigens. Biochemistry (NY) 5:3254–3272
Springer GF, Tegtmeyer H (1981) Origin of anti-Thomsen-Friedenreich (T) and Tn agglutinins in man and in White Leghorn chicks. Br J Haematol 47:453–460
Springer GF, Tegtmeyer H, Huprikar SV (1972) Anti-N reagents in elucidation of the genetical basis of human blood-group MN specificities. Vox Sang 22:325–343
Thatcher N, Hashmi K, Chang J, Swindell R, Crowther D (1980) Anti-T antibody in malignant melanoma patients. Cancer 46:1378–1382
Vaith P, Uhlenbruck G (1978) The Thomsen agglutination phenomenon: a discovery revisited 50 years later. Z Immun Forsch 154:1–14
Vincent RG, Pickren JW, Lane WW, Bross I, Takita H, Houten L, Gutierrez AC, Rzepka T (1977) The changing histopathology of lung cancer. Cancer 39:1647–1655
Weiser MM, Podolsky DK, Isselbacher KJ (1976) Cancer-associated iso-enzyme of serum galactosyltransferase. Proc Natl Acad Sci USA 73:1319–1322
Hashimoto T, Fukuoka M, Nagasawa S, Tamai S, Kusunoki Y, Kawahara M, Furuse K, Sawamura K, Fujimoto T (1979) Small cell carcinoma of the lung and its histological origin. Am J Surg Pathol 3:343–351
Churg A (1978) The fine structure of large cell undifferentiated carcinoma of the lung. Human Pathol 9:143:156
Miller RA, Levy R (1981) Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2:226–230
Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal P, Schlossman SF (1981) Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141–152
Tisserand-Jochem EM (1979) La polyagglutination des globules rouges, étude de deux types de polyagglutinabilité acquisé. These L'université Pierre et Marie Curie, Paris
Vos GH, Brain P (1981) Heterophile antibodies, immunoglobulin levels, and the evaluation of anti-T activity in cancer patients and controls. South Afr Med J 60:133–136
Vos GH, Rose EF, Vos D (1981) Antibody responses to T-activated red cells in children from high- and low-risk areas of cancer of the oesophagus in Transkei. South Afr Med J 59:56–60
Summers JL, Coon JS, Weinstein, RS, Rose M, Ward BS, Falor WH (1981) Prognostic significance of T antigen detection in urinary bladder carcinoma. Am Urol Assoc N Centr Sec 55:45
Author information
Authors and Affiliations
Additional information
Dedicated to H.M.S., who courageously lived from age 48 through 54 with bilateral mastectomies for primary cancers, volunteered throughout 6 years invaluable participation in unestablished immunological procedures, and died with dignity of carcinomatosis
Supported by U.S. Public Health Service Grants CA 19083 and CA 22540, American Cancer Society Research Development Program Grant RD-133, a gift from the Mobil fndn. and Cancer Res. Inst. N.Y. G.F.S. is Julia S. Michels Investigator in Surgical Oncology
Rights and permissions
About this article
Cite this article
Springer, G.F., Murthy, S.M., Desai, P.R. et al. Patients' immune response to breast and lung carcinoma-associated thomsen-friedenreich (T) specificity. Klin Wochenschr 60, 121–131 (1982). https://doi.org/10.1007/BF01711276
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01711276
Key words
- T Antigen and carcinoma
- Anti-T antibody and carcinoma
- Delayed-type hypersensitivity to carcinoma-associated T antigen
- Adenocarcinoma-associated T specificity